By Michele Maatouk
Date: Friday 07 Oct 2022
LONDON (ShareCast) - (Sharecast News) - PureTech Health said on Friday that it has exchanged indicative, non-binding proposals with US biopharmaceutical company Nektar Therapeutics regarding a possible combination.
Responding to press speculation a day earlier, PureTech said that it remains in discussions with Nektar about the proposal.
There can be no certainty that any firm offer will be made, nor as to the terms of any such offer, it said, adding that a further announcement will be made as and when appropriate.
Under UK takeover rules, Nektar has until 1700 BST on 3 November to either announce a firm intention to make an offer for the company or walk away.
Email this article to a friend
or share it with one of these popular networks: